LY75

Summary

LY75 (lymphocyte antigen 75, HGNC:6729) is a protein-coding gene on chromosome 2q24.2, encoding Lymphocyte antigen 75 (O60449). Acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment.

Predicted to enable signaling receptor activity. Predicted to be involved in immune response and inflammatory response. Located in extracellular exosome.

Source: NCBI Gene 4065 — RefSeq curated summary.

At a glance

• GWAS associations: 38
• Clinical variants (ClinVar): 35 total
• Druggable target: yes
• MANE Select transcript: NM_002349

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6729
Approved symbol	LY75
Name	lymphocyte antigen 75
Location	2q24.2
Locus type	gene with protein product
Status	Approved
Aliases	DEC-205, CLEC13B, CD205
Ensembl gene	ENSG00000054219
Ensembl biotype	protein_coding
OMIM	604524
Entrez	4065

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000263636, ENST00000471164, ENST00000484559, ENST00000492955, ENST00000971950, ENST00000971951

RefSeq mRNA: 1 — MANE Select: NM_002349 NM_002349

CCDS: CCDS2211

Canonical transcript exons

ENST00000263636 — 35 exons

Exon	Start	End
ENSE00001187455	159803355	159805222
ENSE00003472109	159810526	159810675
ENSE00003478680	159875444	159875643
ENSE00003490945	159819726	159819920
ENSE00003507252	159864839	159864920
ENSE00003507571	159878324	159878493
ENSE00003512448	159808449	159808571
ENSE00003517893	159853630	159853697
ENSE00003532434	159834044	159834211
ENSE00003533081	159854360	159854535
ENSE00003536202	159816806	159817032
ENSE00003542279	159904589	159904756
ENSE00003546901	159831670	159831786
ENSE00003548427	159893914	159894084
ENSE00003555833	159872451	159872593
ENSE00003565521	159849980	159850140
ENSE00003569345	159898688	159899059
ENSE00003572344	159835480	159835645
ENSE00003572426	159885153	159885293
ENSE00003572893	159890213	159890377
ENSE00003575606	159842245	159842374
ENSE00003582585	159806973	159807140
ENSE00003605527	159850362	159850467
ENSE00003617469	159840729	159840955
ENSE00003617814	159879259	159879369
ENSE00003627357	159882124	159882315
ENSE00003638768	159878633	159878721
ENSE00003658457	159854904	159854939
ENSE00003661457	159815405	159815573
ENSE00003669149	159860821	159860889
ENSE00003677666	159852201	159852340
ENSE00003684310	159858362	159858476
ENSE00003688157	159886420	159886530
ENSE00003690451	159881083	159881240
ENSE00003691260	159853273	159853352

Expression profiles

Bgee: expression breadth ubiquitous, 242 present calls, max score 97.01.

FANTOM5 (CAGE): breadth broad, TPM avg 8.6491 / max 470.5980, expressed in 804 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
31457	8.6491	804

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
thymus	UBERON:0002370	97.01	gold quality
epithelium of nasopharynx	UBERON:0001951	96.09	gold quality
jejunal mucosa	UBERON:0000399	95.22	gold quality
bronchial epithelial cell	CL:0002328	94.36	gold quality
mucosa of paranasal sinus	UBERON:0005030	93.72	gold quality
epithelium of bronchus	UBERON:0002031	93.15	gold quality
nasal cavity epithelium	UBERON:0005384	92.90	gold quality
bronchus	UBERON:0002185	92.75	gold quality
upper leg skin	UBERON:0004262	91.28	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.18	gold quality
colonic mucosa	UBERON:0000317	91.14	gold quality
mammary duct	UBERON:0001765	90.92	gold quality
epithelium of mammary gland	UBERON:0003244	90.72	gold quality
pancreatic ductal cell	CL:0002079	90.53	gold quality
bone marrow cell	CL:0002092	90.08	gold quality
vermiform appendix	UBERON:0001154	90.08	gold quality
nasal cavity mucosa	UBERON:0001826	89.99	gold quality
lymph node	UBERON:0000029	89.78	gold quality
palpebral conjunctiva	UBERON:0001812	89.42	gold quality
bone marrow	UBERON:0002371	89.37	gold quality
trabecular bone tissue	UBERON:0002483	89.08	gold quality
duodenum	UBERON:0002114	88.88	gold quality
mononuclear cell	CL:0000842	88.44	gold quality
leukocyte	CL:0000738	88.41	gold quality
monocyte	CL:0000576	88.34	gold quality
epithelial cell of pancreas	CL:0000083	87.61	gold quality
caecum	UBERON:0001153	86.53	gold quality
rectum	UBERON:0001052	86.44	gold quality
tonsil	UBERON:0002372	85.57	gold quality
ileal mucosa	UBERON:0000331	84.96	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.98

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

123 targeting LY75, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-559	99.95	72.28	3609

Literature-anchored findings (GeneRIF, showing 23)

• Hodgkin’s lymphoma cell lines express a fusion protein encoded by intergenically spliced mRNA for the multilectin receptor DEC-205 (CD205) and a novel C-type lectin receptor DCL-1 (PMID:12824192)
• DCs and DEC-205 can cross-present several different peptides from a single protein. Data supports testing of alphaDEC-205 fusion mAb as a protein-based vaccine. (PMID:17229838)
• CD205 is a sensitive and specific marker for thymoma but its sensitivity to thymic carcinoma is lower than CD5 and CD117. (PMID:17592270)
• targeting EBV nuclear antigen 1 to human DEC-205 receptor, in the presence of the DC maturation stimulus poly(I:C), expanded EBNA1-specific CD4 and CD8 memory T cells; these lymphocytes control the outgrowth of autologous EBV-infected B cells (PMID:18519810)
• oxLDL uptake by DCs is mediated by the scavenger-receptors LOX-1, CD36, and CD205 (PMID:19203752)
• Induction of LY75 antigen is associated with relapsed chronic myeloid leukemia. (PMID:19706888)
• observed that TLR-mediated signaling increases DEC-205 expression levels without affecting receptor internalization (PMID:21413003)
• Upregulation of LY75 is associated with ovarian tumor. (PMID:21887537)
• CD205+ conventional dendritic cells impacts the regulation of T-cell immunity and homeostasis in vivo (PMID:22736794)
• Data indicate that the interaction between the PE-Cy5.5 conjugates and the cells expressing mDEC205 appears distinctive, since none of the PE-Cy5.5 conjugates bind to the cells that express human DEC205 on surface. (PMID:22841832)
• The most significantly associated SNPs to type 2 diabetes mellitus in this study are expression SNPs to the lymphocyte antigen 75 gene, the ubiquitin-specific peptidase 36 gene, and the phosphatidylinositol transfer protein, cytoplasmic 1 gene. (PMID:22865700)
• DEC-205 is a cell surface receptor for CpG olligonucleotides. (PMID:22988114)
• elevated in cholesteatoma (PMID:24702227)
• Variants in LY75 were associated with a Crohn’s disease phenotype involving erythema nodosum. (PMID:25557950)
• results suggest that DEC205 is an immune receptor that recognizes apoptotic and necrotic cells specifically through a pH-dependent mechanism (PMID:26039988)
• High LY75 expression is associated with metastasis of ovarian cancer. (PMID:26871602)
• keratins are the cellular ligands of human DEC205. (PMID:27821726)
• LY75 Gene Polymorphisms are Associated with Inflammatory Bowel Disease. (PMID:27965521)
• IL-6, DEC205, and CD86 can be predictive biomarkers for the respiratory and immune effects of ambient PM2.5. (PMID:28056587)
• combined panel had the highest sensitivity and specificity at 96.3% and 100%, which was significantly or marginally higher than those of EZH2, C-KIT, and CD205 alone (PMID:29487009)
• LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/beta-Catenin Pathway. (PMID:32156068)
• LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model. (PMID:32679765)
• Interaction of human dendritic cell receptor DEC205/CD205 with keratins. (PMID:38301891)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ly75	ENSDARG00000053113
mus_musculus	Ly75	ENSMUSG00000026980
rattus_norvegicus	Ly75	ENSRNOG00000007012

Paralogs (4): MRC2 (ENSG00000011028), PLA2R1 (ENSG00000153246), CD302 (ENSG00000241399), MRC1 (ENSG00000260314)

Protein

Protein identifiers

Lymphocyte antigen 75 — O60449 (reviewed: O60449)

Alternative names: C-type lectin domain family 13 member B, DEC-205, gp200-MR6

All UniProt accessions (1): O60449

UniProt curated annotations — full annotation on UniProt →

Function. Acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment. Causes reduced proliferation of B-lymphocytes.

Subcellular location. Membrane.

Tissue specificity. Expressed in spleen, thymus, colon and peripheral blood lymphocytes. Detected in myeloid and B-lymphoid cell lines. Isoform 2 and isoform 3 are expressed in malignant Hodgkin lymphoma cells called Hodgkin and Reed-Sternberg (HRS) cells.

Post-translational modifications. N-glycosylated.

Miscellaneous. Isoform 2 and isoform 3 are produced in HRS cells by a transcriptional control mechanism which cotranscribe an mRNA containing LY75 and CD302 prior to generating the intergenically spliced mRNA to produce LY75/CD302 fusion proteins. Produced by intergenic splicing of LY75 and CD302. Produced by intergenic splicing of LY75 and CD302.

Isoforms (5)

UniProt ID	Names	Canonical?
O60449-1	4	yes
O60449-2	2, Fusion protein variant V34-2
Q8IX05-2	5
O60449-3	3, Fusion protein variant V33-2
Q8IX05-1	1

RefSeq proteins (1): NP_002340* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000562	FN_type2_dom	Domain
IPR000772	Ricin_B_lectin	Domain
IPR001304	C-type_lectin-like	Domain
IPR013806	Kringle-like	Homologous_superfamily
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR035992	Ricin_B-like_lectins	Homologous_superfamily
IPR036943	FN_type2_sf	Homologous_superfamily
IPR050111	C-type_lectin/snaclec_domain	Family

Pfam: PF00040, PF00059, PF24562

UniProt features (195 total): strand 90, helix 27, turn 17, glycosylation site 14, disulfide bond 13, domain 12, sequence variant 12, modified residue 3, topological domain 2, splice variant 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
8K8H	X-RAY DIFFRACTION	2.79
7JPT	ELECTRON MICROSCOPY	3.2
8HBC	X-RAY DIFFRACTION	3.35
7JPU	ELECTRON MICROSCOPY	5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60449-F1	75.73	0.14

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 933, 1703, 1719

Disulfide bonds (13): 169–194, 183–209, 247–340, 317–332, 389–485, 462–477, 597–614, 840–930, 904–922, 1060–1080, 1197–1211, 1488–1502, 1635–1650

Glycosylation sites (14): 135, 345, 377, 529, 843, 865, 934, 1076, 1103, 1225, 1320, 1392, 1593, 1626

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 228 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, LU_IL4_SIGNALING, GOBP_INFLAMMATORY_RESPONSE, STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GOCC_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, chr2q24, RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN, STEARMAN_TUMOR_FIELD_EFFECT_UP, SCHLOSSER_SERUM_RESPONSE_DN, SANSOM_APC_TARGETS_DN, PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN

GO Biological Process (3): endocytosis (GO:0006897), inflammatory response (GO:0006954), immune response (GO:0006955)

GO Molecular Function (2): carbohydrate binding (GO:0030246), signaling receptor activity (GO:0038023)

GO Cellular Component (4): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
defense response	1
immune system process	1
response to stimulus	1
binding	1
molecular transducer activity	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1276 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LY75	CD209	Q9NNX6	866
LY75	CLEC4A	Q9UMR7	864
LY75	CTAG1A	P78358	853
LY75	CLEC9A	Q6UXN8	787
LY75	CD207	Q9UJ71	784
LY75	ITGAX	P20702	776
LY75	CD40	P25942	731
LY75	CLEC7A	Q9BXN2	722
LY75	CD86	P42081	719
LY75	CD4	P01730	718
LY75	CD8A	P01732	713
LY75	CD80	P33681	708
LY75	IL4	P05112	672
LY75	TLR4	O00206	669
LY75	FCGR3A	P08637	668

IntAct

5 interactions, top by confidence:

A	B	Type	Score
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
CSNK2B	TUBAL3	psi-mi:“MI:0914”(association)	0.350
LY75	glnG	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (2): LY75 (Affinity Capture-MS), LY75 (Affinity Capture-MS)

ESM2 similar proteins: A3FM55, B4XSY7, B4XSY8, B4XSZ1, C0HKZ6, D1MGU0, F1QVU0, O09037, O60449, O75596, O89103, O93426, P06681, P14371, P18292, P19221, P21180, P23132, P25031, P28824, P30836, P35230, P35231, P49259, P49260, P81017, P81112, P98131, Q08731, Q09GJ8, Q09GK0, Q13018, Q28008, Q3SYW2, Q4PRD2, Q568T5, Q5R880, Q60767, Q62028, Q6T7B5

Diamond homologs: A0ZT93, B0VXV2, B4XT08, B5U6Y6, B5U6Y7, C0HKZ7, O60449, P05140, P06027, P06734, P0DJL5, P10716, P13611, P14371, P20693, P34472, P55066, P55067, P81018, P81282, P81996, Q01758, Q02988, Q26627, Q28062, Q28670, Q28858, Q4PRD0, Q4TU93, Q4V885, Q61830, Q62059, Q64449, Q66S03, Q6X5S2, Q6X5S3, Q6X5S5, Q6X5S6, Q6X5S7, Q6X5S8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

35 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	6
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

4924 predictions. Top by Δscore:

Variant	Effect	Δscore
2:159808443:ACTT:A	donor_loss	1.0000
2:159808444:CTTA:C	donor_loss	1.0000
2:159808447:A:AC	donor_gain	1.0000
2:159808447:A:AG	donor_loss	1.0000
2:159808447:A:AT	donor_loss	1.0000
2:159808447:AC:A	donor_gain	1.0000
2:159808448:C:CA	donor_gain	1.0000
2:159808448:C:CC	donor_gain	1.0000
2:159808448:CC:C	donor_gain	1.0000
2:159808448:CCA:C	donor_gain	1.0000
2:159808448:CCAA:C	donor_gain	1.0000
2:159808567:GTGAT:G	acceptor_gain	1.0000
2:159808568:TGAT:T	acceptor_gain	1.0000
2:159808569:GAT:G	acceptor_gain	1.0000
2:159808570:AT:A	acceptor_gain	1.0000
2:159808571:TC:T	acceptor_loss	1.0000
2:159808572:C:CA	acceptor_loss	1.0000
2:159808572:C:CC	acceptor_gain	1.0000
2:159808572:C:CG	acceptor_loss	1.0000
2:159808574:G:C	acceptor_gain	1.0000
2:159808575:T:C	acceptor_gain	1.0000
2:159808575:T:TC	acceptor_gain	1.0000
2:159810652:A:C	acceptor_gain	1.0000
2:159815440:A:C	donor_gain	1.0000
2:159817030:CAA:C	acceptor_gain	1.0000
2:159817033:C:CC	acceptor_gain	1.0000
2:159831668:A:AC	donor_gain	1.0000
2:159831669:C:CC	donor_gain	1.0000
2:159831669:CTT:C	donor_gain	1.0000
2:159831787:C:CC	acceptor_gain	1.0000

AlphaMissense

11483 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:159898830:C:A	W108C	0.999
2:159898830:C:G	W108C	0.999
2:159898947:C:A	W69C	0.998
2:159898947:C:G	W69C	0.998
2:159842300:C:A	W1075C	0.997
2:159842300:C:G	W1075C	0.997
2:159898906:C:G	C83S	0.997
2:159898907:A:T	C83S	0.997
2:159898953:C:A	W67C	0.997
2:159898953:C:G	W67C	0.997
2:159835535:C:A	W1206C	0.996
2:159835535:C:G	W1206C	0.996
2:159842302:A:G	W1075R	0.996
2:159842302:A:T	W1075R	0.996
2:159858381:C:A	W788C	0.996
2:159858381:C:G	W788C	0.996
2:159864902:C:A	W712C	0.996
2:159864902:C:G	W712C	0.996
2:159875591:C:A	W609C	0.996
2:159875591:C:G	W609C	0.996
2:159864904:A:G	W712R	0.995
2:159864904:A:T	W712R	0.995
2:159872555:C:A	W671C	0.995
2:159872555:C:G	W671C	0.995
2:159878427:C:A	W557C	0.995
2:159878427:C:G	W557C	0.995
2:159890295:C:A	W240C	0.995
2:159890295:C:G	W240C	0.995
2:159898734:C:A	W140C	0.995
2:159898734:C:G	W140C	0.995

dbSNP variants (sampled 300 via entrez): RS1000020040 (2:159868591 A>T), RS1000049809 (2:159868944 A>G), RS1000050244 (2:159869602 C>G,T), RS1000054858 (2:159880291 A>C), RS1000070654 (2:159835324 G>A), RS1000071693 (2:159806497 T>C), RS1000086947 (2:159816088 T>C,G), RS1000109218 (2:159818443 A>G), RS1000131547 (2:159828012 G>A), RS1000174387 (2:159873523 C>G,T), RS1000264078 (2:159866596 T>A,C), RS1000310386 (2:159886273 A>G), RS1000329096 (2:159815128 C>G,T), RS1000367707 (2:159835027 C>T), RS1000420298 (2:159822625 G>T)

Disease associations

OMIM: gene MIM:604524 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

38 associations (top):

Study	Trait	p-value
GCST000984_1	Idiopathic membranous nephropathy	9.000000e-29
GCST002729_2	Crohn’s disease-related phenotypes	2.000000e-06
GCST003043_85	Inflammatory bowel disease	3.000000e-08
GCST003044_22	Crohn’s disease	1.000000e-06
GCST004603_214	Platelet count	3.000000e-17
GCST004607_221	Plateletcrit	2.000000e-22
GCST004607_222	Plateletcrit	4.000000e-29
GCST004607_248	Plateletcrit	4.000000e-10
GCST004626_19	Myeloid white cell count	2.000000e-09
GCST005973_22	White blood cell count	5.000000e-10
GCST005974_11	Neutrophil count	3.000000e-09
GCST005991_2	Platelet count	7.000000e-16
GCST007277_3	Tourette syndrome	2.000000e-07
GCST010916_9	Proportion of activated microglia (inferior temporal cortex)	2.000000e-06
GCST90002389_130	Lymphocyte percentage of white cells	3.000000e-16
GCST90002390_380	Mean corpuscular hemoglobin	9.000000e-12
GCST90002392_220	Mean corpuscular volume	7.000000e-16
GCST90002395_342	Mean platelet volume	2.000000e-15
GCST90002396_223	Mean reticulocyte volume	4.000000e-17
GCST90002398_353	Neutrophil count	1.000000e-12
GCST90002398_354	Neutrophil count	3.000000e-11
GCST90002399_117	Neutrophil percentage of white cells	2.000000e-09
GCST90002400_331	Plateletcrit	4.000000e-54
GCST90002400_332	Plateletcrit	2.000000e-10
GCST90002400_333	Plateletcrit	2.000000e-12
GCST90002400_334	Plateletcrit	7.000000e-28
GCST90002400_335	Plateletcrit	4.000000e-22
GCST90002400_336	Plateletcrit	1.000000e-12
GCST90002402_252	Platelet count	1.000000e-40
GCST90002402_253	Platelet count	3.000000e-11

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007985	platelet crit
EFO:0004833	neutrophil count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0004527	mean corpuscular hemoglobin
EFO:0010701	mean reticulocyte volume
EFO:0007990	neutrophil percentage of leukocytes
EFO:0004305	erythrocyte count
EFO:0004736	aspartate aminotransferase measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4804258 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Lymphocyte antigens

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	7
entinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
GSK-J4	decreases expression	1
Asian ginseng	decreases expression, decreases reaction, affects cotreatment	1
pirinixic acid	decreases expression, increases activity, increases expression, affects binding	1
trichostatin A	increases expression	1
potassium chromate(VI)	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
quinocetone	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Acetaminophen	increases expression	1
Cytarabine	increases expression	1
Diethylhexyl Phthalate	decreases expression, decreases reaction, affects cotreatment	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Iron	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	affects expression	1
Vitamin D	affects expression	1
Cyclosporine	increases expression	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.